Key facts
- This page summarizes Laura Damme's Form 4 filing for TransMedics Group, Inc. (TMDX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2023, 19:00.
Laura Damme - 20 Feb 2023 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)
- Reporting relationship
- VP, Clinical Affairs
- Issuer ticker
- TMDX
- Reported as of
- 20 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2023, 19:00:40 UTC
- Prior SEC filing
- 16 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Stephen Gordon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Laura Damme filed Form 4 for TransMedics Group, Inc. (TMDX) on 22 Feb 2023.
Change
- Previous filing in this sequence was filed on 16 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TMDX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,685
- Change %
- Price
- $0.000000
- Shares after
- 5,685
- Date
- 20 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TMDX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +8,705
- Change %
- Price
- $0.000000
- Shares after
- 8,705
- Date
- 20 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,705
- Exercise price
- $66.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 20, 2023 until the option is fully vested on February 20, 2027, subject to continued service.